Sinar Mas Multiartha Injects Rp1.43 Trillion into Subsidiaries

Strategic Capital Injection

PT Sinar Mas Multiartha Tbk (SMMA) has made a significant capital injection of Rp1.43 trillion into three of its subsidiaries in December 2025. This strategic move comes as the company approaches the end of the financial year, demonstrating its commitment to supporting the growth and financial stability of its subsidiaries.

Distribution of Capital

The capital injection was distributed across three subsidiaries: PT Hyundai Capital Finance Indonesia received Rp109.45 billion on December 23, 2025. PT Shinta Utama received the largest share at Rp1.32 trillion, facilitated through a debt-to-equity swap following approval from an Extraordinary General Meeting of Shareholders (EGMS) on December 22, 2025. The third subsidiary, while not named in the disclosure, received the remaining amount.

Business Implications

This capital injection demonstrates SMMA's proactive approach to managing its subsidiaries' financial health and supporting their business operations. The debt-to-equity swap with PT Shinta Utama particularly highlights SMMA's strategic financial management, potentially improving the subsidiary's balance sheet and operational capacity.

Financial Impact

The total investment of Rp1.43 trillion represents a significant financial commitment by SMMA to its subsidiaries. This move is likely to enhance the financial stability and growth prospects of the recipient companies, potentially leading to improved overall group performance in the future.